Medical services provider Iqvia led a $15m series C round today for BC Platforms, a Switzerland-based genomic data management and analytics spinout of Massachusetts Institute of Technology.
The round was also backed by Debiopharm Innovation Fund, a strategic investment vehicle for biopharmaceutical development group Debiopharm, and Finnish government-owned investment firm Finnish Industry Investment (Tesi).
BC Platforms provides pharmaceutical developers with genomic data management and analytics services which underpin the progression of gene-driven precision medicines.
The funding will be used to enhance the company’s automated drug development services, building on existing industry partnerships with healthcare providers and biobanks.
Iqvia invested through a strategic partnership it expects will strengthen its genotypic-phenotypic database product, E360 Genomics. E360 allows scientists to undertake human biology and drug discovery research in a secure environment that respects patient privacy.
BC Platforms and Iqvia will work towards developing new genomic data-driven technology, and Iqvia will gain representation on the BC’s board of directors.
Debiopharm Innovation Fund led a $10m series B round for BC Platforms in mid-2017, participating with Tesi and undisclosed other existing investors.
Rob Kotchie, president for real-world solutions at Iqvia, said: “Drawing insights from integrated clinical-genomics data is a growing need of our life science and healthcare customers.
“Through the combination of BC Platforms technologies – which automates the workflow from genomic instruments to actionable insights – with Iqvia’s leading real-world technologies platform we can enable customers to conduct novel research and discover new insights to advance healthcare.”
The original version of this article appeared on our sister site, Global University Venturing.